Skip to main content

Table 2 Univariate Cox regression analysis of factors associated with survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

From: Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy

Variables OS PFS
B SE Wald c2 HR 95% CI P B SE Wald c2 HR 95% CI P
Gender (female vs male) 0.53 0.32 2.73 1.70 0.91–3.19 .099 0.42 0.30 1.86 1.51 0.83–2.75 0.173
Age (< 65 y vs ≥ 65 y) 0.02 0.33 0.00 1.02 0.53–1.94 0.955 0.21 0.31 0.44 1.23 0.67–2.27 0.507
Tumor location (middle/lower vs upper) 0.34 0.28 1.50 1.41 0.81–2.45 0.220 0.23 0.26 0.77 1.26 0.76–2.09 0.379
NACT cycle (< 3 vs ≥ 3) 0.00 0.28 0.00 1.00 0.58–1.73 0.999 0.07 0.25 0.08 1.08 0.65–1.77 0.774
Histologic grade (poorly vs well/moderately) 0.75 0.35 4.54 2.12 1.06–4.23 .033 0.65 0.31 4.35 1.92 1.04–3.54 .037
Margin status (R1 vs R0) 0.72 0.39 3.50 2.06 0.97–4.38 .061 0.67 0.36 3.48 1.96 0.97–3.99 .062
TRG (3 vs 0–2) 0.95 0.31 9.13 2.58 1.40–4.79 .003 0.78 0.28 7.92 2.18 1.27–3.75 .005
Lymph node ratio (> 30% vs ≤ 30%) 2.10 0.30 49.19 8.21 4.56–14.78 < .001 1.87 0.26 50.11 6.48 3.86–10.86 < .001
  1. Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard ratio, CI Confidence interval, NACT Neoadjuvant chemotherapy, TRG Tumor regression grade